Needham raised the firm’s price target on Celcuity (CELC) to $122 from $95 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Celcuity (CELC): Strengthened Gedatolisib Data and Priority Review Drive Reiterated Buy Rating and Higher Price Target
- Celcuity reports results from PIK3CA WT cohort of Phase 3 VIKTORIA-1 trial
- Celcuity Adds Veteran Director to Strengthen Oncology Strategy
- Short Report: Celcuity short interest continues to grow
- Celcuity announces FDA accepted for filing its NDA for gedatolisib